Fabino Enterprises Ltd
Incorporated in 2011, Fabino Enterprises manufactures, markets, trades, and does packing of pharmaceutical and other wellness focused consumer products[1]
- Market Cap ₹ 4.27 Cr.
- Current Price ₹ 20.3
- High / Low ₹ 27.0 / 13.0
- Stock P/E
- Book Value ₹ 18.7
- Dividend Yield 0.00 %
- ROCE -6.22 %
- ROE -8.76 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Stock is trading at 1.09 times its book value
- Company's working capital requirements have reduced from 174 days to 137 days
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of -1.44% over last 3 years.
- Company has high debtors of 405 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 2.76 | 7.52 | 3.06 | 4.19 | 3.36 | 6.01 | 18.01 | 11.42 | |
| 2.44 | 7.20 | 2.99 | 4.09 | 3.33 | 5.90 | 17.84 | 12.96 | |
| Operating Profit | 0.32 | 0.32 | 0.07 | 0.10 | 0.03 | 0.11 | 0.17 | -1.54 |
| OPM % | 11.59% | 4.26% | 2.29% | 2.39% | 0.89% | 1.83% | 0.94% | -13.49% |
| 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.00 | 0.29 | 1.30 | |
| Interest | 0.29 | 0.20 | 0.01 | 0.01 | 0.01 | 0.02 | 0.13 | 0.13 |
| Depreciation | 0.03 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.07 | 0.10 |
| Profit before tax | 0.00 | 0.10 | 0.04 | 0.07 | 0.01 | 0.06 | 0.26 | -0.47 |
| Tax % | 30.00% | 25.00% | 28.57% | 0.00% | 16.67% | 50.00% | -25.53% | |
| 0.00 | 0.07 | 0.03 | 0.05 | 0.01 | 0.05 | 0.13 | -0.36 | |
| EPS in Rs | 0.00 | 4.67 | 0.25 | 0.24 | 0.05 | 0.24 | 0.62 | -1.71 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 30% |
| 3 Years: | 50% |
| TTM: | -37% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -377% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -13% |
| 1 Year: | -16% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | -1% |
| Last Year: | -9% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.15 | 0.15 | 1.20 | 2.10 | 2.10 | 2.10 | 2.10 | 2.10 |
| Reserves | 0.45 | 0.52 | 0.10 | 2.00 | 2.01 | 2.06 | 2.19 | 1.83 |
| 2.52 | 1.08 | 0.31 | 0.05 | 0.41 | 0.84 | 1.61 | 1.11 | |
| 5.43 | 1.83 | 0.65 | 0.48 | 0.50 | 4.50 | 7.11 | 12.28 | |
| Total Liabilities | 8.55 | 3.58 | 2.26 | 4.63 | 5.02 | 9.50 | 13.01 | 17.32 |
| 0.10 | 0.08 | 0.16 | 0.17 | 0.15 | 0.24 | 0.46 | 0.37 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 | 0.05 |
| 8.45 | 3.50 | 2.10 | 4.46 | 4.87 | 9.21 | 12.50 | 16.90 | |
| Total Assets | 8.55 | 3.58 | 2.26 | 4.63 | 5.02 | 9.50 | 13.01 | 17.32 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 0.18 | 2.44 | -0.45 | -1.90 | -0.68 | -2.99 | -0.12 | 0.59 | |
| -0.01 | 0.00 | -0.10 | -0.05 | -0.01 | -0.18 | -0.29 | -0.01 | |
| -0.18 | -2.37 | 0.45 | 2.47 | 0.34 | 0.43 | 0.61 | -0.63 | |
| Net Cash Flow | 0.00 | 0.07 | -0.10 | 0.52 | -0.35 | -2.75 | 0.20 | -0.05 |
| Free Cash Flow | 0.17 | 2.44 | -0.54 | -1.95 | -0.69 | -3.11 | -0.41 | 0.58 |
| CFO/OP | 56% | 772% | -600% | -1,900% | -2,233% | -2,700% | 6% | -38% |
Ratios
Standalone / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 338.55 | 113.09 | 158.64 | 125.44 | 274.84 | 377.75 | 174.70 | 405.27 |
| Inventory Days | 988.71 | 15.36 | 62.61 | 174.83 | 147.24 | 88.59 | 26.56 | 28.69 |
| Days Payable | 1,024.81 | 77.34 | 63.94 | 34.76 | 45.78 | 294.40 | 143.21 | 374.56 |
| Cash Conversion Cycle | 302.45 | 51.11 | 157.31 | 265.51 | 376.29 | 171.94 | 58.05 | 59.40 |
| Working Capital Days | 19.84 | 51.93 | 165.80 | 292.70 | 444.30 | 282.40 | 103.16 | 137.43 |
| ROCE % | 12.32% | 2.98% | 2.78% | 0.46% | 1.68% | 7.16% | -6.22% |
Insights
In beta| Mar 2019 | Mar 2020 | Jun 2021 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Exports as % of total revenue % |
|
|||||
| Number of permanent employees count |
||||||
| Capacity utilization (in-house products) % |
||||||
| In-house manufacturing capacity (Protein/Malt Powder) tonnes per annum |
||||||
| Number of active products/SKUs count |
||||||
| Number of domestic distributors count |
||||||
| Number of export distributors/agents count |
||||||
| Top 5 customer concentration % |
||||||
Extracted by Screener AI
Documents
Announcements
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
-
Announcement under Regulation 30 (LODR)-Change in Management
- Board appointed Samrat Vardhan Dutta, Sarthak Goyal and Rahul Mangla as directors on 29 Sep 2026.
-
Board Meeting Outcome for Meeting Of Board Of Director Held On September 29, 2026.
- Board appointed Samrat Vardhan Dutta, Sarthak Goyal and Rahul Mangla as additional directors on 29 Sep 2026.
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
- Fabino Enterprises held its 15th AGM on September 29, 2026; agenda included sale of subsidiary business shares.
- Closure of Trading Window
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
Business Overview:[1][2]
a) FEL is an ISO 9001:2015 pharmaceutical company located near the Delhi NCR region. It offers a wide range of allopathic and herbal products.
b) Company markets pharmaceutical formulation for domestic market and sells through own distribution network and sales force under
their own brand name
c) It gets Ayurvedic formulations manufactured through Loan Licensing facilities, Packing, Labelling etc.
d) Company exports wellness and FMCG products like Coffee, Malt powder, Protein powder, Hair shampoo which it also markets